Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
FDG-PET has recently emerged as an important tool for the management of Hodgkins lymphoma. Although its use for initial staging and response evaluation at the end of treatment is well established, the place of interim PET for response assessment and subsequent treatment tailoring is still quite cont...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2011/430679 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850168072620474368 |
|---|---|
| author | M. André T. Vander Borght A. Bosly |
| author_facet | M. André T. Vander Borght A. Bosly |
| author_sort | M. André |
| collection | DOAJ |
| description | FDG-PET has recently emerged as an important tool for the management of Hodgkins lymphoma. Although its use for initial staging and response evaluation at the end of treatment is well established, the place of interim PET for response assessment and subsequent treatment tailoring is still quite controversial. The use of interim PET after a few cycles of chemotherapy may allow treatment reduction for good responders, leading to lesser treatment toxicities as well as early treatment adaptation for bad responders with a potential higher chance for cure. Interpretation of interim PET is a rapidly moving field. Actually, visual interpretation is preferred over quantitative interpretation in this situation. The notion of minimal residual uptake emerged for faint persisting FDG uptake, but has evolved during the recent years. Guidelines using mediastinum and liver as references have been proposed at the expert meeting in Deauville 2009. Actually, several trials are ongoing both for localised and advanced disease to evaluate the FDG-PET potential for early treatment monitoring and tailoring. Until the results of these prospective randomized trials become available, treatment changes according to the interim PET results should remain inappropriate and limited to well-conducted clinical trials. |
| format | Article |
| id | doaj-art-e661eba52e304b32a488b764aa2c0df0 |
| institution | OA Journals |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-e661eba52e304b32a488b764aa2c0df02025-08-20T02:21:03ZengWileyAdvances in Hematology1687-91041687-91122011-01-01201110.1155/2011/430679430679Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and CaveatsM. André0T. Vander Borght1A. Bosly2Department of Hematology, Grand Hôpital de Charleroi, Grand Rue, 3, 6000 Charleroi, BelgiumDepartment of Nuclear Medecine, Université Catholique de Louvain, Cliniques Universitaires UCL de Mont Godinne, Yvoir, BelgiumDepartment of Hematology, Université Catholique de Louvain, Cliniques Universitaires UCL de Mont Godinne, Yvoir, BelgiumFDG-PET has recently emerged as an important tool for the management of Hodgkins lymphoma. Although its use for initial staging and response evaluation at the end of treatment is well established, the place of interim PET for response assessment and subsequent treatment tailoring is still quite controversial. The use of interim PET after a few cycles of chemotherapy may allow treatment reduction for good responders, leading to lesser treatment toxicities as well as early treatment adaptation for bad responders with a potential higher chance for cure. Interpretation of interim PET is a rapidly moving field. Actually, visual interpretation is preferred over quantitative interpretation in this situation. The notion of minimal residual uptake emerged for faint persisting FDG uptake, but has evolved during the recent years. Guidelines using mediastinum and liver as references have been proposed at the expert meeting in Deauville 2009. Actually, several trials are ongoing both for localised and advanced disease to evaluate the FDG-PET potential for early treatment monitoring and tailoring. Until the results of these prospective randomized trials become available, treatment changes according to the interim PET results should remain inappropriate and limited to well-conducted clinical trials.http://dx.doi.org/10.1155/2011/430679 |
| spellingShingle | M. André T. Vander Borght A. Bosly Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats Advances in Hematology |
| title | Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats |
| title_full | Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats |
| title_fullStr | Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats |
| title_full_unstemmed | Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats |
| title_short | Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats |
| title_sort | interim fdg pet scan in hodgkin s lymphoma hopes and caveats |
| url | http://dx.doi.org/10.1155/2011/430679 |
| work_keys_str_mv | AT mandre interimfdgpetscaninhodgkinslymphomahopesandcaveats AT tvanderborght interimfdgpetscaninhodgkinslymphomahopesandcaveats AT abosly interimfdgpetscaninhodgkinslymphomahopesandcaveats |